1001 ET - The steep selloff in Sarepta Therapeutics shares following the death of a patient who received its Elevidys gene therapy is likely overdone, Mizuho's Uy Ear says in a brief note. Mizuho says while acute liver injury is a known side effect of Elevidys, this is the first case of acute liver failure leading to death after more than 800 patients have been treated, and that the individual who died had a recent cytomegalovirus infection, which can damage the liver. Mizuho, with an outperform rating and $190 price target on Sarepta, says it still see the Elevidys benefit/risk profile as positive. Sarepta tumbles 23% to $78. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
March 18, 2025 10:01 ET (14:01 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。